Participated · Series C · May 2026

HeyGears began as a digital dentistry-focused company producing resin-based 3D printers used for orthodontic appliances, crowns, prosthetics, and surgical guides. Since its 2015 founding in Guangzhou, the company has broadened into a wider 3D printing ecosystem with its Reflex printer series targeting industrial production, creative markets, and prosumer customers. HeyGears is investing in AI software, new materials, and automation to support that expansion and to build recurring-revenue streams from consumables. The company reports roughly 70% of revenue comes from consumables rather than one-time printer sales. It holds over 400 patents related to its high-precision printing technologies and has prior institutional rounds including a 2018 Series A and a 2019 $60M Series B. HeyGears has also participated in collaborative projects such as the RapidVent ventilator effort during the COVID-19 pandemic.

Led · Series A · Jan 2026

Founded in September 2023 by Feng Fan and Peng Zongyang, Yanhe Technology develops perovskite light-energy batteries and photovoltaic solutions for consumer electronics and space applications. The company has built a 100MW-level fully automated perovskite mass-production line for the consumer-grade market and supplies products across dozens of categories, including cameras, smart door locks, electronic photo frames, keyboards, and mice. Its products have entered the supply chains of more than 100 brands in over 50 countries and regions, with customers including Lenovo, Samsung, and members of the Xiaomi ecosystem. Yanhe pursues a two-track strategy: quickly monetize consumer-grade products to generate stable cash flow while using those resources to advance space photovoltaics. It has formed strategic partnerships with Zhongke Tiansuan and HangSheng Satellite to develop lightweight, high-stowage-ratio satellite solar wings with plans for on-orbit verification and staged satellite launches beginning in 2026. The company targets revenue of over 100 million yuan in 2026 and aims to reach break-even in the first half of 2027.

Participated · Equity · Sep 2022

UnionTech is a leader in the 3D printing industry, offering a full ecosystem that spans 3D printers, proprietary printing materials, software, and end-to-end application services. The company serves more than 3,000 customers across over 50 countries and regions, with major markets in China, Europe, North America, Asia Pacific, and the Middle East. Management plans to channel new capital into developing advanced printing materials, expanding product lines, and building a comprehensive printing system platform. Additional funds will support the promotion of additive manufacturing applications in existing and new industries. UnionTech’s strategy centers on maintaining technological leadership while scaling its global footprint. Financially, the company most recently secured a $30 million Pre-IPO round after having closed a Series D round in November of the previous year, underscoring steady investor confidence in its growth prospects.

Participated · Series A · Mar 2021

OnQuality Pharmaceuticals develops targeted cancer supportive care therapies intended to address toxicities from cancer treatments. The company is based in Seattle, WA and Shanghai, China. Its lead candidate, OQL011, is a topical ointment designed to treat moderate to severe hand-foot skin reaction (HFSR) and is being evaluated in a multicenter, randomized Phase II trial in the U.S. Two additional onco-dermatology agents, OQL023 (for EGFR-inhibitor-induced skin rash) and OQL033 (for chemotherapy-induced hand-foot syndrome), are in IND-enabling preclinical studies and are expected to enter clinical trials in 8–12 months. OnQuality is also developing targeted supportive-care agents for gastrointestinal and bone marrow toxicities related to chemotherapies, HER2/EGFR-targeted therapies, and immuno-oncology agents, with multiple programs anticipated to enter clinical development over the next 18 months. The company has raised a total of $35M across its Series A and A+ financings to support these development programs. 岸阔医药 focuses on supportive treatments in oncology that address unmet clinical needs and aim to improve cancer patients' quality of life. The company has built a pipeline covering six indications and maintains R&D teams in both Shanghai and Seattle. Founded less than two years ago, it has advanced programs spanning clinical and preclinical stages. The recent financing will support a U.S. multi-center Phase II clinical trial, clinical filings and early clinical studies for two follow-on products, and early research across multiple preclinical projects. The article does not disclose revenue or user metrics. Company leadership states the funding will accelerate pipeline progress and help address high-incidence treatment side effects.

Participated · Series B · Sep 2020

Baijiayun provides cloud-based video software that enables training agencies and corporate clients to deliver livestreaming courses, on-demand video classes, and video conferences. The company moved quickly to meet explosive demand for cloud video services from the education and corporate training sectors during the COVID-19 pandemic. Baijiayun has acquired three companies and integrated them into its in-house product suite, and it plans to continue making acquisitions. Founder and CEO Li Gangjiang, previously CTO of Sohu's video unit, says the company aims to build multiple product lines and grow substantially. Baidu is among the company's investors and has previously backed Baijiayun. New funding will be used for hiring, sales network expansion, R&D, and mergers and acquisitions. Baijiayun was founded in 2017 and is based in Beijing.